PCSK9 and coronary artery disorder: The global assessment of plaque regression with a PCSK9 antibody measured by intravascular ultrasound (GLAGOV) trial demonstrated that the addition of evolocumab to the treatment of patients with CAD who were pre-treated with statins had a favourable effect on the progression of coronary atherosclerosis as measured by intravascular ultrasound (IVUS) [79].